Snowball logo
logo
HNGZ

Hangzhou Tigermed Consulting Co. Ltd

HNGZY โ€ข PINK
$4.45$0.00ย  (0%)
Estimate
P/E
222.5
EPS
0.02
Beta
0.433
Growth
Revenue, YoY
19%
Net income, YoY
-323.35%
FCF, YoY
24.27%
Dividends
Dividend yield
0.41%
Annual payout
$0.02
Next ex. div date
June 22, 27
Payout
62.7%
Div.rating
About the company
Ticker
HNGZY
ISIN
US41044T1088
Country
China
Sector (GICS)
Healthcare
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Frequently asked questions

What sector does Hangzhou Tigermed Consulting Co. Ltd (HNGZY) operate in?

Hangzhou Tigermed Consulting Co. Ltd belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is Hangzhou Tigermed Consulting Co. Ltd (HNGZY) current stock price?

As of the latest data, Hangzhou Tigermed Consulting Co. Ltd stock price is $4.45, with a previous close of $4.45.

What is Hangzhou Tigermed Consulting Co. Ltd (HNGZY) current market capitalization?

Hangzhou Tigermed Consulting Co. Ltd market cap is approximately 547.91 million.

What is Hangzhou Tigermed Consulting Co. Ltd (HNGZY) Earnings Per Share (EPS)?

The trailing EPS is $0.02.

What is Hangzhou Tigermed Consulting Co. Ltd (HNGZY) Price-to-Earnings (P/E) ratio?

Hangzhou Tigermed Consulting Co. Ltd current P/E ratio is 222.5.

What is Hangzhou Tigermed Consulting Co. Ltd (HNGZY) EBITDA?

Hangzhou Tigermed Consulting Co. Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 32.93 million.

Does Hangzhou Tigermed Consulting Co. Ltd (HNGZY) pay dividends?

Yes. Hangzhou Tigermed Consulting Co. Ltd pays annual dividends with an annualized yield of 0.41% and an estimated annual payout of $0.02 per share.

When is the next ex-dividend date for Hangzhou Tigermed Consulting Co. Ltd (HNGZY)?

The next ex-dividend date is scheduled for June 22, 2027.

What is Hangzhou Tigermed Consulting Co. Ltd (HNGZY) beta (volatility) score?

Hangzhou Tigermed Consulting Co. Ltd has a beta of 0.433, indicating lower volatility than the overall market.